Characteristics of human Ewing/PNET sarcoma models

por Teicher, Beverly A., Bagley, Rebecca G., Rouleau, Cecile, Kruger, Ariel, Ren, Yi, Kurtzberg, Leslie
Publicado 2011

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

por Debeurme, Franck, Lacout, Catherine, Moratal, Claudine, Bagley, Rebecca G, Vainchenker, William, Adrian, Francisco, Villeval, Jean-Luc
Publicado 2015

Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia

por NGUYEN, TRI-HUNG, WEBER, WILLIAM, HAVARI, EVIS, CONNORS, TIMOTHY, BAGLEY, REBECCA G., McLAREN, RAJASHREE, NAMBIAR, PRASHANT R., MADDEN, STEPHEN L., TEICHER, BEVERLY A., ROBERTS, BRUCE, KAPLAN, JOHANNE, SHANKARA, SRINIVAS
Publicado 2012

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

por Bardia, Aditya, Kaklamani, Virginia, Wilks, Sharon, Weise, Amy, Richards, Donald, Harb, Wael, Osborne, Cynthia, Wesolowski, Robert, Karuturi, Meghan, Conkling, Paul, Bagley, Rebecca G., Wang, Yamei, Conlan, Maureen G., Kabos, Peter
Publicado 2021

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions...

por Jager, Agnes, de Vries, Elisabeth G. E., der Houven van Oordt, C. Willemien Menke-van, Neven, Patrick, Venema, Clasina M., Glaudemans, Andor W. J. M., Wang, Yamei, Bagley, Rebecca G., Conlan, Maureen G., Aftimos, Philippe
Publicado 2020

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

por Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Publicado 2021

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

por Issa, Ghayas C., Aldoss, Ibrahim, DiPersio, John, Cuglievan, Branko, Stone, Richard, Arellano, Martha, Thirman, Michael J., Patel, Manish R., Dickens, David S., Shenoy, Shalini, Shukla, Neerav, Kantarjian, Hagop, Armstrong, Scott A., Perner, Florian, Perry, Jennifer A., Rosen, Galit, Bagley, Rebecca G., Meyers, Michael L., Ordentlich, Peter, Gu, Yu, Kumar, Vinit, Smith, Steven, McGeehan, Gerard M., Stein, Eytan M.
Publicado 2023